Skip to main content

Table 2 Age, gender, VTE incidence and all-cause mortality following hip arthroplasty in relation to indication for surgery

From: Symptomatic venous thromboembolism and mortality in orthopaedic surgery – an observational study of 45 968 consecutive procedures

Type of surgery

Number of procedures (n = 4001)

Median age- (25th-75th percentile)

Female gender - n (%)

Mortality – n (%)

All VTE – n (%; 95% CI)

PE – n (%; 95% CI)

DVT – n (%; 95% CI)

Total hip replacement

       

-Degenerative hip disorder

1691

71.1 (62–78)

1101 (65.1)

10 (0.6; 0.3-1.1)

40 (2.4; 1.7-3.2)

14 (0.8; 0.5-1.4)

28 (1.7; 1.1-2.4)

- Fracture

348

78.5 (73–83)

272 (78.2)

9 (2.6; 1.3-5.0)

10 (2.9; 1.5-5.3)

3 (0.9; 0.3-2.7)

7 (2.0; 1.0-4.2)

- Fracture sequelae

522

77.9 (70–84)

392 (75.1)

13 (2.5; 1.4-4.3)

14 (2.7; 1.6-4.5)

6 (1.2; 0.5-2.6)

8 (1.5; 0.8-3.1)

Hemiarthroplasty

       

- hip fracture

743

84.9 (80–89)

565 (76.0)

71 (9.6; 7.6-12.1)

7 (0.9; 0.4-2.0)

6 (0.8; 0.4-1.8)

1 (0.1; 0.02-1.0)

- Fracture sequelae

239

84.9 (81–90)

192 (80.3)

15 (6.3; 3.8-10.4)

3 (1.3; 0.4-3.9)

0

3 (1.3; 0.4-3.9)

Hip prosthesis revision

429

74.8 (64–82)

251 (58.5)

3 (0.7; 0.2-2.2)

5 (1.2; 0.5-2.8)

0

5 (1.2; 0.5-2.8)

Hip replacement - malignancy

29

64.3 (58–78)

21 (72.4)

1 (3.4; 0.5-24.5)

1 (3.4; 0.5-24.5)

0

1 (3.4; 0.5-24.5)

  1. Thromboprophylaxis was used for 7 to 10 days.
  2. Fracture sequelae = osteonecrosis of the femoral head or non-union and or implant failure after hip fracture surgery.